| Official Website | http://2020apfp.com/program-at-a-glance_o.php?class_id=1 |
| Event | 2020 Asian Pacific Federation of Pharmacologists Conference |
| Time | May 4-7, 2020 |
| Location | Taipei, Taiwan |
| Early Bird Registration | March 10, 2020 |
| Online Registration | April 10, 2020 |
| On-site Registration | September 27-29, 2020 |
| Time and Venue for the Opening Lecture |
18:00-19:00, September 27, 2020 201 Meeting Room,2F, Taipei International Convention Center |
| Speaker | Prof. Tasuku Honjo 2014 Tang Prize laureate in Biopharmaceutical Science 2018 Nobel Prize winner in Medicine or Physiology |
| Title | Cancer Immunotherapy: Efficacy Improvement and Adverse Effect Prevention |
| Summary | In 1992, Prof. Honjo discovered the checkpoint molecule PD-1 and the crucial role it plays in allowing cancer cells to evade the antitumor immune response. He and many other researchers have since successfully developed several antibodies targeting PD-1. One such antibody, nivolumab (Opdivo®), had produced complete or partial responses in patients with non-small-cell lung cancer, melanoma, and renal-cell carcinoma in clinical trials and has received its first FDA approval in 2014, opening a new chapter in cancer treatment and increasing the survival rates of cancer patients. He and Dr. James P. Allison were awarded the Tang Prize in 2014 and together they won the 2018 Nobel Prize in Physiology or Medicine. In this lecture, he will share with the audience his research on immunotherapy. |